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Background: The acyclic retinoid, peretinoin, has been shown to be effective for suppressing hepatocellular
carcinoma (HCC) recurrence after definitive treatment in a small-scale randomized clinical trial. However, little has
been documented about the mechanism by which peretinoin exerts its inhibitory effects against recurrent HCC in
humans in vivo.
Methods: Twelve hepatitis C virus-positive patients whose HCC had been eradicated through curative resection or
ablation underwent liver biopsy at baseline and week 8 of treatment with either a daily dose of 300 or 600 mg
peretinoin. RNA isolated from biopsy samples was subjected to gene expression profile analysis.
Results: Peretinoin treatment elevated the expression levels of IGFBP6, RBP1, PRB4, CEBPA, G0S2, TGM2, GPRC5A,
CYP26B1, and many other retinoid target genes. Elevated expression was also observed for interferon-, Wnt-, and
tumor suppressor-related genes. By contrast, decreased expression levels were found for mTOR- and tumor
progression-related genes. Interestingly, gene expression profiles for week 8 of peretinoin treatment could be
classified into two groups of recurrence and non-recurrence with a prediction accuracy rate of 79.6% (P<0.05). In
the liver of patients with non-recurrence, expression of PDGFC and other angiogenesis genes, cancer stem cell marker
genes, and genes related to tumor progression was down-regulated, while expression of genes related to hepatocyte
differentiation, tumor suppression genes, and other genes related to apoptosis induction was up-regulated.
Conclusions: Gene expression profiling at week 8 of peretinoin treatment could successfully predict HCC recurrence
within 2 years. This study is the first to show the effect of peretinoin in suppressing HCC recurrence in vivo based on
gene expression profiles and provides a molecular basis for understanding the efficacy of peretinoin.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon form of cancer worldwide, and it is estimated that
there are more than 740,000 new cases each year [1].
Early-stage HCC is indicated for definitive treatment by
surgical resection or local therapy [2-4]; however, the* Correspondence: mhonda@m-kanazawa.jp
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reproduction in any medium, provided the orprognosis of HCC is typically poor, and around 50% of pa-
tients experience recurrence within 3 years of definitive
therapy [5-7]. Indeed, some researchers estimate that the
3-year recurrence rate is higher than 70% for hepatitis C
virus (HCV)-positive patients [8], and past clinical experi-
ence with interferon-based therapy, systemic chemother-
apy, and other treatment modalities has shown the lack of
effective standard therapy for suppressing tumor recur-
rence after definitive treatment for HCC [9-11].
Peretinoin (NIK-333) has only been reported to suppress
HCC recurrence in a small-scale randomized controlledLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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finitive treatment received oral administration of 600 mg
peretinoin daily for one year. The results showed that
peretinoin significantly reduced the incidence of recurrent
or new HCC [12] and improved patient survival rates [13].
Based on the results of rat pharmacological studies [14,15]
and a phase I clinical study of peretinoin [16], a phase II/III
clinical study of peretinoin was conducted in which the
doses were set at 300 and 600 mg daily. The study demon-
strated that, in the Child-Pugh A subgroup, 600 mg/day
peretinoin (n=100) reduced the risk of HCC recurrence or
death by approximately 40% compared to placebo (n=106)
[hazard ratio (HR)=0.60; 95% confidence interval (CI):
0.40–0.89)] [17]. On the other hand, 300 mg daily doses of
peretinoin were insufficient for tumor control and showed
no substantial difference from the placebo [17]. A large-
scale clinical study including several countries is now
planned to confirm the clinical efficacy of peretinoin.
Little is known about the mechanism by which
peretinoin exerts its inhibitory effects against recurrent
HCC in humans in vivo. In order to investigate this
mechanism, we conducted here a comparative study
recruiting HCV-positive patients who successfully com-
pleted definitive treatment for HCC (similar to the phase
II/III clinical study mentioned above). Patients under-
went liver biopsy before and after 8 weeks of treatment
with repeated doses of peretinoin, and the collected
samples were analyzed for gene expression profiling
using the remnant liver after eradication of HCC. We
found that changes in the gene expression signature ob-
served in this study help us to understand the means by
which peretinoin suppresses HCC, in particular its in-
hibition against de novo carcinogenesis.
Methods
Patients
We enrolled 12 HCV-positive patients who were cured
of their primary and first recurrent HCC by surgical hep-
atectomy or radiofrequency ablation therapy and other
non-surgical local treatments (Table 1). Complete tumor
removal was confirmed by dynamic computed tomog-
raphy (CT) scans. Inclusion criteria were as follows: posi-
tive presence of HCV-RNA in the serum; Child-Pugh
class A or B liver function; platelet counts ≥50,000/μL;
and age ≥20 years. Exclusion criteria included the fol-
lowing: positive for hepatitis B surface antigen; tumor
infiltration into the portal vein; use of transarterial
embolization or transarterial chemoembolization (TAE/
TACE) for definitive therapy; postoperative use of investi-
gational medicinal products, antitumor agents, interferon,
or vitamin K2 formulations; blood pressure unmanageable
even with medication (systolic pressure ≥160 mmHg or
diastolic pressure ≥100 mmHg); complication with renal
impairment, cardiovascular disease, diabetes mellitus,autoimmune disease, asthma, or other severe disease;
presence of neoplasm; allergy to CT contrast media; al-
lergy to retinoids; history of total gastrectomy; possible
pregnancy during study; and lactating mothers.
Study design
This trial was a randomized, parallel-group, open-label
study. Twelve eligible patients signed the informed con-
sent form for registration. They were randomized to re-
ceive one of the two peretinoin doses: 600 or 300 mg
per day. Each dose group consisted of 6 patients.
After randomization, patients underwent liver biopsy
before the start of peretinoin treatment, then orally
received peretinoin twice daily for 8 weeks. At the
end of the 8-week therapy, they underwent a second
liver biopsy (Figure 1A). The collected biopsy samples
were kept in RNAlaterW solution (Ambion Inc., Austin,
TX) at 4°C overnight or longer. Within 3 days, the
biopsy samples were removed from the RNAlater so-
lution and partially subjected to RNA extraction and
purification. The purified RNA samples were stored
at −80°C until required for gene expression profiling.
The remaining part of the biopsy samples was used
to determine the intrahepatic peretinoin concentra-
tion. Samples were placed in polypropylene bottles
containing 99.5% ethanol, and the air in the bottle
was purged with argon. The bottles were tightly closed
and stored at −80°C protected from light. Peripheral
blood samples were also collected for the analysis of
gene expression signatures and to determine plasma
peretinoin levels.
After the second biopsy, patients were orally ad-
ministered peretinoin twice daily for 88 weeks. Dur-
ing the treatment period, patients visited the hospital
every 4 weeks for check-ups, drug compliance, and
protocol-specified medical examinations. Drug com-
pliance was assessed by pill counts. During the study,
use of anticancer agents, interferon, vitamins K and
A, and antiviral drugs (e.g., rivabirin) was prohibited.
The study was registered at the Japan Pharmaceutical
Information Center (JapicCTI-121757). This protocol
was approved by the Institutional Review Board of
Kanazawa University for clinical investigation follow-
ing the provisions of Helsinki, Good Clinical Practice
guidelines, local laws, and regulations. Written informed
consent was obtained from all patients involved in this
study. The detail protocol of this study is presented in
Additional file 1: Study protocol.
Plasma peretinoin concentration
A 5-mL blood sample was drawn into an EDTA-2Na
tube, immediately mixed, and centrifuged to obtain a
plasma sample. The air in the sample tubes was replaced
with argon, and the tubes were stored at −80°C protected
Table 1 Patient characteristics and prognosis
Patient Dose Age Sex P/R Curative MTD Tumor no. Tumor Background liver CP ALT PLT Prognosis
no. treatment histology F A 2 yrs 4.5 yrs
1 300 70 F P RFA 15 2 m-p 4 2 A 112 7.9 Rec Rec
2 600 72 F R RFA 20 2 w 4 2 A 40 7.9 Rec Rec λ
3 300 58 M P resection 25 1 m-p 2 1 A 16 19.2 nonRec nonRec
4 600 54 M P resection 25 1 m-p 3 2 A 57 16.4 nonRec Rec
5 600 60 F P RFA 23 1 m-p 4 2 B 23 6.4 nonRec nonRec
6 300 73 F P RFA 20 2 m-p 3 2 A 31 14.2 Rec Rec λ
7 300 69 F P RFA 11 3 w-m 4 1 A 38 11.5 Rec Rec λ
8 600 74 F P RFA 16 2 m-p 4 1 A 45 5.1 nonRec Rec
9 600 65 M R RFA 10 1 m-p 2 1 A 29 16.5 nonRec nonRec
10 600 59 M P resection 34 1 m-p 4 2 B 60 9.4 nonRec nonRec
11 300 70 F R RFA 15 1 w-m 4 2 B 98 7 nonRec nonRec
12 300 66 M P RFA 15 1 m-p 4 1 A 90 10.6 nonRec nonRec
Dose (mg/day), ALT(U/L), PLT(×104/μL), MTD (mm).
F; female, M; male, P; primary HCC, R; (first) recurrent HCC, MTD; maximum tumor diameter, w; well-differentiated, m; moderately differentiated, p; poorly
differentiated, F; fibrosis stage, A; activity grade, CP; Child-Pugh classification, ALT; alanine aminotransferase, PLT; platelet.































Figure 1 Peretinoin pharmacokinetics study design and change of gene expression profiling. A: Peretinoin pharmacokinetics study design.
Twelve patients were enrolled in the study and two groups of 6 patients were randomly administered one of two doses of peretinoin (600 or
300 mg per day) for 8 weeks. A liver biopsy was obtained before the start of peretinoin administration and 8 weeks into the treatment. After the
second liver biopsy, oral administration of peretinoin twice daily was resumed for 88 weeks. B: Hierarchical clustering analysis of patients using all
expressed genes. Patient numbers (Table 1) and peretinoin dose are listed. Patients with HCC recurrence are shown in red and boxed. There was
no significant association between hepatic gene expression and HCC recurrence before starting peretinoin treatment, while distinct clusters of
patients were observed after week 8 depending on HCC recurrence.
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form of peretinoin and its lipid-bound form were de-
termined as follows: first, the peretinoin-containing
fractions were extracted from the plasma samples,
then subjected to derivatization of peretinoin, and the
concentration of the derivative was measured by li-
quid chromatography-atmospheric pressure chemical
ionization-tandem mass spectrometry.
Liver peretinoin concentration
Collected liver tissue samples were immersed in 99.5%
ethanol in containers, and the internal air was replaced
with argon. The samples were stored at −80°C protected
from light. The liver concentrations of the unchanged
form of peretinoin and its lipid-bound form were deter-
mined as for the plasma concentrations above.
Microarray analysis
For gene expression profiling of the liver, in-house
cDNA microarrays containing a representative panel of
10,000 liver-specific genes (Kanazawa liver chip 10K ver.
2.0) were used. RNA isolation, amplification of antisense
RNA, labeling, and hybridization were conducted as pre-
viously described [18].
To identify genetic variants, paired t-tests were
performed using BRB-Array Tools software (http://linus.
nci.nih.gov/BRB-ArrayTools.html) to define P-values <0.05
as gene variants. Hierarchical cluster analysis, exploration
of significantly expressed genes, and class prediction were
also performed using the BRB-Array Tools.
Hierarchical clustering was carried out using centered
correlation and average linkage. The class comparison tool
in the BRB-Array Tools was used to extract significantly
expressed genes. Genes whose expression levels were sig-
nificantly different between two groups were located by the
t-test at the P<0.002 significance level. Univariate permuta-
tion tests were repeated 1,000–2,000 times to control for
errors. Class prediction was performed using the
above-mentioned significantly differentiated genes as
discriminators, and the results were cross-validated
using seven algorithms: compound-covariate predictor,
diagonal linear discriminant analysis, 1-nearest neigh-
bor, 3-nearest neighbors, nearest centroid, support vec-
tor machine, and Bayesian compound covariate. The
mean value of the seven success rates for class predic-
tion was defined as the prediction accuracy rate [18].
Pathway analysis was performed using MetaCore™
(Thomson Reuters, New York, NY) and functional ontol-
ogy enrichment analysis was performed to find diffe-
rentially expressed pathway using differentially expressed
genes [18,19].
The microarray data have been submitted to the Gene
Expression Omnibus (GEO) public database at NCBI
(Accession No. GSE29302).Quantitative real-time detection polymerase chain reaction
Quantitative real-time detection polymerase chain reac-
tion (RTD-PCR) was performed using the TaqMan Uni-
versal Master Mix (PE Applied Biosystems, Foster City,
CA). Primer pairs and probes were purchased from the
TaqMan assay reagents library. Standard curves were
generated for each assay using RNA derived from nor-
mal human liver tissue. Expression data were normalized
by GAPDH, and the results are shown as the relative
fold expression to the normal liver.
Statistical analysis
Results are expressed as means ± S.D. Significance was
tested by one-way ANOVA with Bonferroni’s method,




In this study, 88 adverse events were recorded in
12 patients (100%). Major adverse events included
rhinopharyngitis (n=7), blood pressure elevation (n=5),
peripheral edema (n=3), and enteritis (n=3). Most of
these adverse events were mild or moderate, and were
adequately controlled. Nine serious adverse events
were documented in 5 patients, including hypergly-
cemia (n=2) and coronary stenosis (n=1). However, all
reported serious adverse events were alleviated with ap-
propriate treatment, and there was no substantial con-
cern identified regarding the safety of peretinoin.
Plasma peretinoin concentration
Plasma peretinoin concentrations were determined at
week 8 of treatment. The mean (± SD) plasma concen-
trations of the unchanged form of peretinoin were 82.3
(± 90.0) and 201.2 (± 111.4) ng/mL at 4 h post-dose
and 35.8 (± 49.2) and 29.0 (±17.9) ng/mL at 8 h post-
dose for the 300 and 600 mg per day groups, respect-
ively. The plasma concentrations of the unchanged
peretinoin measured at 4 h post-dose (≈ tmax) were
dose-dependent. The mean (± SD) plasma concentra-
tions of the lipid-bound form of peretinoin were 1478.8
(± 853.7) and 2789.8 (± 1630.0) ng/mL at 4 h post-dose
and 1227.8 (± 942.7) and 2213.2 (± 1156.1) ng/mL at 8 h
post-dose for the 300 and 600 mg per day groups, respect-
ively. The plasma concentrations of the lipid-bound form
of peretinoin were dose-dependent at 4 and 8 h post-dose.
Liver peretinoin concentration
Liver peretinoin concentrations were determined at
week 8 of treatment. The measurements of the liver con-
centration of the unchanged form of peretinoin were all
below the lower limit of quantitation at 4 h post-dose
for all 6 patients in the 300 mg per day group. For the
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of 0.052 and 0.059 μg/g, while the remaining 4 patients
produced results under the lower limit of quantitation
(0.050 μg/g). The mean (± SD) concentrations of the
lipid-bound form of peretinoin were 13.7508 (± 11.1097)
and 12.8345 (± 8.7048) μg/g for the 300 and 600 mg per
day groups, respectively.
Gene expression analysis
To analyze the gene expression signature of the liver tissue,
we identified genes whose expression levels were signifi-
cantly different before and after the start of the peretinoin
treatment (Figure 1A). The identified genes were candi-
dates for peretinoin-responsive genes. The phase II/III clin-
ical study showed that a daily dose of 600 mg peretinoin
reduced the risk of HCC recurrence, while a 300 mg dose
was not significantly different from the placebo [17].
Therefore, gene expression patterns were compared before
and after the start of the 600 mg peretinoin therapy (n=6).
Consequently, 424 hepatic genes showed significantly dif-
ferent expression levels from baseline at week 8 (enhance-
ment and suppression seen for 190 and 234 genes,
respectively). Typical examples of these genes are repre-
sented in Table 2 where fold changes of gene expression
for the 300 mg and 600 mg doses are shown respectively.
In addition to the retinoid-induced genes, genes related to
interferon, tumor suppressors, negative regulators of Wnt
signaling, insulin-like growth factor (IGF) signaling, and
hepatocyte differentiation were significantly up-regulated
by peretinoin. By contrast, genes related to the mammalian
target of rapamycin (mTOR), tumor progression, cell cycle,
and metastasis/angiogenesis were down-regulated. Serial
changes in peretinoin-responsive gene expression are
shown in Additional file 2: Figure S1. Significant changes
in expression were observed in response to 600 mg of
peretinoin, while changes in expression were minimal with
300 mg of peretinoin.
Hierarchical clustering of patients using hepatic gene
expression prior to administering peretinoin revealed
no significant association with clinical outcome, but a
significant association became clearly apparent 8 weeks
after peretinoin treatment (Figure 1B). The patients
were clustered into two groups: one containing patients
with HCC recurrence (4 of 5 patients had recurrence)
and the other containing those without recurrence (all
6 patients were recurrence free) within 2 years. Super-
vised learning methods using seven different algorithms
showed that the patients receiving treatment could be
differentiated into two groups with or without recur-
rence by 224 gene predictors (P<0.002) at 79.6% accur-
acy (P<0.05) (Table 3). Interestingly, 44 of 224 (20%)
genes were peretinoin induced.
Although peretinoin-responsive genes were more in-
duced in patients treated with the 600 mg dosage, geneexpression profiling 8 weeks after peretinoin treatment
could not be classified according to the dosage (Table 3).
This might be because two patients treated with the
300 mg dosage (No. 11 and No. 12) had already
expressed high levels of peretinoin-response genes be-
fore starting peretinoin treatment (Additional file 2:
Figure S1). Interestingly, patients with high levels of
peretinoin-response genes before treatment (No. 9–12)
did not show HCC recurrence during the entire obser-
vation period (4.5 years; Table 1).
Hierarchical clustering of all 12 patients using 224
gene predictors is shown in Figure 2A. Clear gene clus-
ters were observed according to patients with recur-
rence and those without, with the exception of one
patient (No. 3, Table 1). Interestingly, in the liver of pa-
tients with non-recurrence, genes related to angiogenesis,
cancer stem cells, Wnt signaling, and tumor progression
were repressed, while genes inducing differentiation,
tumor suppression, and apoptosis were up-regulated
(Figure 2B, Table 4). Interestingly, PDGF-C was the most
significant predictor to differentiate patients who will ex-
perience recurrence within 2 years (Table 4).
Consistent with these results, hierarchical clustering
using pre-defined curated gene sets based on the NCBI’s
Cancer Genome Anatomy Project similarly differentiated
patients into two groups with or without HCC recur-
rence (Figure 3). Among angiogenesis-related genes,
PDGF-C, PDGF-B, vascular endothelial growth factor
(VEGF)-B, VEGF-D, and fibroblast growth factor-basic
(FGF-2) were repressed in patients without recurrence.
As for cell signaling-related genes, MYC, SRC, and
RAS-related genes were also repressed; retinoid X recep-
tor alpha (RXRA) and CCAAT/enhancer binding protein
(C/EBP), alpha were up-regulated in patients without re-
currence. Some cytokines (IL-7, IL-13, and IL-18) and
chemokines (e.g. CXCL7) were repressed, while major
histocompatibility complex molecules and interferon-
related molecules (e.g. IFNAR2) were up-regulated in
patients without recurrence (Figure 3).
cDNA microarray analysis revealed that among these
predictors, the mRNA level of PDGF-C was the most
significant predictor for differentiating patients who will
experience recurrence within 2 years (Table 4). This ob-
servation was also assessed by RTD-PCR (Figure 4). The
expression of the catalytic enzyme of retinoic acid,
CYP26B1, was significantly up-regulated at around 200
fold by peretinoin treatment, but its expression was
equally induced in patients with or without recurrence.
However, the expression of RAR-β, a retinoid receptor,
was significantly up-regulated by peretinoin in patients
without HCC recurrence (Figure 4).
Patients were followed up for a further 3 years (mean:
2.5 ± 0.5 years) after the cessation of peretinoin treat-
ment. Other two patients experienced recurrence during
Table 2 Representative genes significantly up-regulated or down-regulated in response to peretinoin treatment
Parametric p-value Ratios (Under/Pre) Description Symbol GB acc
600 mg 600 mg 300 mg
Up-regulated genes in response to peretinoin treatment
Retinoid target genes
0.0002 1.85 1.25 Cytochrome P450, family 26, subfamily B, polypeptide 1 CYP26B1 NM_019885
0.004 1.75 1.33 Insulin-like growth factor binding protein 6 IGFBP6 NM_002178
0.005 1.42 1.16 Regulatory factor X-associated ankyrin-containing protein RFXANK NM_134440
0.006 1.33 1.30 Putative lymphocyte G0/G1 switch gene G0S2 NM_015714
0.013 1.54 0.90 Retinol binding protein 1 RBP1 NM_002899
0.014 1.56 0.87 Retinol binding protein 4 RBP4 NM_006744
0.034 1.27 1.07 Retinoic acid induced 3 GPRC5A AI923823
0.040 1.22 1.19 Transglutaminase 2 TGM2 AI962033
0.044 1.23 1.14 CCAAT/enhancer binding protein (C/EBP), alpha CEBPA NM_004364
Interferon-related genes
0.029 1.45 0.93 Guanylate binding protein 1, interferon-inducible, 67kDa GBP1 NM_002053
0.047 1.39 0.94 Interferon-induced protein 44 IFI44 NM_006417
0.048 1.28 1.05 Chemokine (C-X-C motif) ligand 9 CXCL9 NM_002416
Negative regulator of Wnt and TGF-β signaling
0.004 1.54 1.06 BMP and activin membrane-bound inhibitor homolog BAMBI NM_012342
0.008 1.45 1.11 Secreted frizzled-related protein 5 SFRP5 NM_003015
Anti-angiogenesis
0.021 1.37 0.98 Thrombomodulin THBD NM_000361
0.038 1.28 0.99 Protein C receptor, endothelial (EPCR) PROCR NM_006404
Tumor suppressor related
0.029 1.35 0.96 Jumonji domain containing 3 JMJD3 XM_043272
0.029 1.39 0.91 Jumping translocation breakpoint JTB NM_006694
0.034 1.39 1.32 Protein kinase, AMP-activated, alpha 2 catalytic subunit PRKAA2 NM_006252
Down-regurated genes in response to peretinoin treatment
mTOR-related-gene
0.045 0.78 0.94 FK506 binding protein 12-rapamycin associated protein 1 FRAP1 NM_004958
Cytokine and growth factor
0.019 0.77 1.25 Interleukin 13 IL13 NM_002188
0.031 0.74 1.00 Hepatocyte growth factor HGF NM_000601
Tumor progression related
0.011 0.73 0.94 Junctional adhesion molecule 3 JAM3 NM_032801
0.013 0.70 1.00 V-myc myelocytomatosis viral oncogene homolog Myc NM_002467
0.017 0.73 1.12 Src-like-adaptor SLA NM_006748
0.028 0.78 1.10 Cell division cycle 2, G1 to S and G2 to M CDC2 NM_001786
0.030 0.66 0.95 BCL2-associated athanogene BAG1 NM_004323
0.039 0.64 0.93 Chemokine (C-C motif) receptor 9 CCR9 NM_031200
0.043 0.76 1.13 Pre-B-cell leukemia transcription factor 1 PBX1 H08835
The peretinoin-response genes were identified by comparing hepatic gene expression in the pre and under treatment of 6 patients who were treated with 600
mg dose of peretinoin. The fold changes of gene expression are shown in 300 mg and 600 mg dosage respectively.
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224 79.6 < 0.05
On-treatment 300 mg vs 600 mg 38 72.7 N.S.
Seven algorithms of Compound-Covariate Predictor, Diagonal Linear Discriminant
Analysis 1-Nearest Neighbor, 3-Nearest Neighbors, Nearest Centroid, Support
Vector Machine, and Bayesian Compound Covariate were used for class prediction.
Prediction % was calculated as the average of these seven algorithms.
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Table 1). Three patients with recurrence died at 0.3, 1.9,
and 2.5 years after the cessation of peretinoin treatment.
The Kaplan-Meier estimation of the recurrence-free ra-
tio deduced from 224 gene predictors showed significant
differences in HCC recurrence between patients with
the recurrence expression pattern and those with non-
recurrence expression (P=0.04). Moreover, Kaplan-Meier
estimation of the survival ratio deduced from the same
gene predictors showed a trend for improved survival of
patients with non-recurrence expression patterns com-
pared with those with the recurrence expression pattern
(P=0.12) (Figure 2C, D).
With the exception of the number of tumors at the
time of curative therapy, none of the other clinical pa-
rameters (e.g. peretinoin dose, tumor, background liver
histology, or background liver function) were associated
with the recurrence-free or survival ratio. Thus, the
peretinoin response during the early period of adminis-
tration deduced from the hepatic gene expression pattern




2,4,6,10,14-pentaenoic acid] is expected to be a powerful
agent against HCC recurrence. This synthetic retinoid in-
duces the transcriptional activation of the retinoic acid re-
ceptor (RAR) and retinoid X receptor (RXR), which are
both members of the retinoid receptor family. One primary
pathway of HCC development involves sustained hepatitis
virus infection, which causes repeated cycles of hepatocel-
lular necrosis and proliferation. During increased cell pro-
liferation, mutations occur that lead to the development of
HCC unless the dedifferentiated tumor cells are elimi-
nated by apoptosis. The anti-HCC mechanism of action
of peretinoin has previously been suggested to be a result
of induction of cell apoptosis [20,21], enhancement of cell
differentiation [21,22], suppression of cell proliferation by
elevation of P21 protein expression and suppression of
cyclin D1 expression [23,24]. The first route of action isindependent of retinoid receptors, while the others are
retinoid receptor-dependent, although all mechanisms re-
main largely speculative.
Peretinoin was previously shown to suppress in vivo
hepatocarcinogenesis in 30-methyl-4-dimethylaminoazo-
benzene- and N-diethylnitrosamine-induced rats [14,15,25],
and in hepatoma-bearing mice and transgenic mice ex-
pressing a dominant-negative retinoic acid receptor [25,26].
Recently, we revealed that peretinoin effectively inhibits
hepatic fibrosis and HCC development in Pdgf-c Tg mice.
This demonstrated that PDGF signaling is a target of
peretinoin in preventing the development of hepatic fibro-
sis and HCC [27]. The purpose of this study was to investi-
gate how peretinoin exerts its therapeutic potential by
analyzing its effects on the gene expression patterns in clin-
ical samples.
Gene expression profiling in patients without HCC re-
currence demonstrated the promotion of RAR-β expres-
sion, the most common retinoid target gene identified
by basic research. Moreover, the expression of other ret-
inoid target genes such as C/EBP-α, IGFBP6, TGM2,
G0S2, RBP1, RBP4, and GPRC5A was also enhanced. Of
these, C/EBP-α, IGFBP6, and TGM2 have been shown to
inhibit HCC proliferation when co-expressed with RAR-
β by all-trans-retinoic acid [28,29]. In addition, the RXR-
selective agonist (rexinoid)-induced expression of IGFBP6,
which occurs following RAR-β-mediated transcriptional ac-
tivation of RAR/RXR, has been shown to suppress tumor
growth [30]. Moreover, G0S2 and GPRC5A have been
reported to possess tumor suppressive or apoptosis-
inducing effects [31,32]. These primary response retinoid
target genes are presumably retinoid-responsive genes. In
addition to enhancing retinoid target gene expression,
peretinoin induced changes in the expression levels of a
variety of genes involved in hepatocarcinogenesis, such as
those related to Wnt signaling, IGF signaling, interferon,
mTOR, and cell cycle regulation. These results suggest that
peretinoin modulates multiple signaling cascades involved
in carcinogenesis, either directly or indirectly. Abnormal-
ities in the genes regulating Wnt signaling, IGF signaling,
interferon, mTOR, and the cell cycle have been indicated
to play a crucial role in the development of HCC [33,34].
We argue that peretinoin suppresses HCC cell prolifera-
tion by improving the expression of these genes, thereby
preventing HCC recurrence.
The cluster analysis performed in this study successfully
differentiated patients with recurrence within 2 years and
those without it. Supervised learning methods identified
224 genes as predictors for HCC recurrence (p<0.002). Im-
portantly, 44 (20%) of these were peretinoin-responsive
genes, suggesting that recurrence-related genes might be
regulated by peretinoin-responsive genes.
A comparison of these groups of patients revealed that
the non-recurrence group was associated with the
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Figure 2 Expression profiling of 224 gene predictors and the prognosis of patients. A: Hierarchical clustering using 224 gene predictors of
patients with or without HCC recurrence. Patients with HCC recurrence within 2 years are shown in red and patients with HCC recurrence after the
cessation of peretinoin are boxed in red. B: Pathway analysis of differentially expressed genes using MetaCore (GeneGo). Functional ontology enrichment
analysis was performed to find differentially expressed pathway maps or map folders using 224 differentially expressed genes (p<0.002) between patients
with and without HCC recurrence. C, D: Kaplan-Meier estimation of recurrence-free ratio (C) and survival ratio (D) of patients with recurrence expression
patterns (red) and those with non-recurrence expression (blue).
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http://www.biomedcentral.com/1471-2407/13/191enhanced expression of genes related to hepatocellular dif-
ferentiation and tumor suppression. The non-recurrence
group also showed reduced expression of the genes pro-
moting liver fibrosis and steatosis and the liver cancer
stem cell marker genes. The genes related to hepatocellu-
lar differentiation, MT1H, MT2A, FOXA1 (HNF3α), and
FOXA3 (HNF3γ), may be secondary response genes regu-
lated by C/EBP-α [35,36]. Indeed, C/EBP-α manifested a
significant shift in expression level before and during
treatment with peretinoin, and could also differentiatebetween recurrence and non-recurrence within 2 years.
Even after the cessation of peretinoin treatment, the ex-
pression of these genes was still significantly related to
HCC recurrence (Figure 2C, D). Thus, we speculate that
the differences in expression levels of peretinoin-response
genes would determine the expression of recurrence-
related genes (Additional file 3: Figure S2).
Interestingly, PDGF-C was the most significant pre-
dictor to differentiate those patients who will experience
recurrence. Using a mouse model of PDGF-C over-
Table 4 Representative genes differentially expressed between HCC recurrence and non-recurrence groups
Parametric p-value t-values Description Symbol GB acc
Up-regulated genes in the recurrence group
Angiogenesis related
0.0001 −5.19 Platelet derived growth factor C PDGFC AI446155
0.0006 −4.37 Sperm equatorial segment protein 1 NOX5 NM_145658
0.0010 −4.13 Interleukin 18 IL18 AI800476
Cancer stem cell related
0.0004 −4.63 Prominin 1 PROM1 NM_006017
0.0018 −3.83 Pyruvate kinase, muscle PKM2 NM_002654
Positive regulator of Wnt
0.0018 −3.84 TGFB-induced factor (TALE family homeobox) TGIF1 AI866302
0.0018 −3.84 NK2 transcription factor related, locus 5 NKX2-5 NM_004387
Tumor progression related
0.0005 −4.47 Transcriptional co-activator with PDZ-binding motif WWTR1 AK025216
0.0017 −3.87 Roundabout, axon guidance receptor, homolog 1 ROBO1 NM_133631
0.0018 −3.84 Hepatitis B virus x associated protein RSF1 NM_016578
0.0019 −3.79 Heat shock 27kDa protein 2 HSPB2 NM_001541
Up-regulated genes in the non-recurrence group
Liver function and hepatocytes differenti related
0.0002 4.88 Metallothionein 2A MT2A NM_005953
0.0002 4.08 CCAAT/enhancer binding protein (C/EBP), alpha CEBPA NM_004364
0.0003 4.72 Forkhead box A3 FOXA3 NM_004497
0.0006 4.42 Hemopexin HPX NM_000613
0.0006 4.35 Metallothionein 1H MT1H NM_005951
0.0013 4.01 Forkhead box A1 FOXA1 NM_004496
0.0014 3.97 FK506 binding protein 8, 38kDa FKBP8 NM_012181
Tumor suppressor related
0.0005 4.51 Deleted in colorectal carcinoma DCC X76132
0.0018 3.84 NK3 transcription factor related, locus 1 NKX3-1 NM_006167
Apoptosis inducing
0.0015 3.93 BH3 interacting domain death agonist BID NM_197967
0.0019 3.82 Programmed cell death 8 AIFM1 NM_145813
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http://www.biomedcentral.com/1471-2407/13/191expression resulting in hepatic fibrosis, steatosis, and
eventually HCC development, peretinoin was previously
shown to significantly repress the development of hep-
atic fibrosis and tumors [27].
Although gene expression profiling analysis was
conducted using the remnant liver after definitive treat-
ment in the present study, past similar research has
demonstrated the possibility of predicting recurrent
metachronous and multicentric HCC [37,38]. The exact
mechanisms of how the expression profile of non-tumor
tissues might determine the recurrence risk are not
known. However, the degree of differentiation of hepato-
cytes and microenvironments such as angiogenesis andfibrogenesis in non-tumor lesions of the liver is likely to
be closely associated with hepatocarcinogenesis. Interest-
ingly, patients with pre-activated peretinoin-response
genes were resistant to HCC recurrence for the entire
observation period (4.5 years).
This study demonstrated that the patient response to
peretinoin during the early period of administration
could predict HCC recurrence and, potentially, patient
survival. However, it should be noted that the current
study protocol consisted of 600 mg peretinoin as the
subsequent maintenance treatment for all patients after
the 8-week start phase (Figure 1A). In addition, we did
not conduct a placebo control to observe serial changes
Figure 3 Hierarchical clustering using pre-defined curated gene sets based on NCBI’s Cancer Genome Anatomy Project. Presented
genes were differentially expressed at P-values <0.05 between patients with and without HCC recurrence.
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http://www.biomedcentral.com/1471-2407/13/191of hepatic gene expression without peretinoin adminis-
tration. Therefore, there might be some limitations in
drawing concrete conclusions from this study.
Although we attempted to analyze the liver peretinoin
concentration in the present study to investigate its pos-
sible relationship with gene expression, peretinoin levelswere too low to yield a meaningful result. However, con-
sidering that gene expression profiling identified signifi-
cant changes in the expression levels of retinoid-related
and other genes before and during peretinoin treatment,


























































































Figure 4 RTD-PCR evaluation of PDGF-C, PROM1, MDK, CYP26B1, and RAR β in the liver of patients with or without HCC recurrence.
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http://www.biomedcentral.com/1471-2407/13/191The previous peretinoin phase II/III clinical study
demonstrated that daily doses of 600 mg peretinoin sig-
nificantly reduced the incidence of HCC recurrence in
HCV-positive patients who underwent definitive treat-
ment. The findings of the present study are complemen-
tary to this as we successfully identified candidates for
the peretinoin-responsive and recurrence-related genes.
These genes are probably involved in the inhibition of
HCC recurrence and could be beneficial as future candi-
date biomarkers of the effectiveness of peretinoin.
Conclusions
In this study, patients underwent liver biopsy before
and after 8 weeks of treatment with repeated doses of
peretinoin. Gene expression profiling at week 8 of
peretinoin treatment could successfully predict HCC
recurrence within 2 years. This study is the first to
show the effect of peretinoin in suppressing HCC re-
currence in vivo based on gene expression profiles
and provides a molecular basis for understanding the
efficacy of peretinoin.
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Additional file 2: Figure S1. One-way hierarchical clustering of
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